文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

供者纯化CD34(+)细胞输注治疗再生障碍性贫血单倍体造血干细胞移植后造血重建不良11例临床分析

[Clinical analysis of donor-purified CD34(+) stem cell boost in 11 patients with poor hematopoietic reconstruction after haploid hematopoietic stem cell transplantation for aplastic anemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

回顾性分析11例再生障碍性贫血患者单倍体造血干细胞移植后造血重建不良接受供者纯化CD34(+)细胞输注,中位随访614天,总生存率90.9%(10/11),输注后慢性GVHD发生率18.2%,未发生急性GVHD。

要点

  • 11例中2例持续性血小板减少、1例原发性植入功能不良、8例继发性植入功能不良。
  • 2例持续性血小板减少患者输注后22天和13天获得血小板恢复。
  • 9例植入功能不良患者中6例获得完全造血恢复,1例部分恢复,2例无效。

核心结论

  • 供者纯化CD34(+)细胞输注可能是治疗再生障碍性贫血患者单倍体造血干细胞移植后造血重建不良的有效方法。

研究设计与样本

  • 回顾性分析2019年1月1日至2024年3月31日在北京大学人民医院接受供者纯化CD34(+)细胞输注的11例单倍体造血干细胞移植后发生造血重建不良的再生障碍性贫血患者。

主要发现

  • 11例中持续性血小板减少2例、原发性植入功能不良1例、继发性植入功能不良8例。
  • 诊断造血重建不良的中位时间为移植后110天(范围60~330天),输注纯化CD34(+)细胞的中位时间为移植后194天(范围125~456天)。
  • 2例持续性血小板减少患者分别在CD34(+)细胞输注后22天、13天获得血小板恢复。
  • 9例植入功能不良患者中6例获得完全造血恢复,中性粒细胞计数中位恢复时间19天(范围8~158天),HGB中位恢复时间32.5天(范围13~158天),血小板计数中位恢复时间31.5天(范围7~171天)。
  • 输注后慢性GVHD发生率为18.2%,未发生急性GVHD;中位随访614天(范围153~1765天),11例中10例存活,总生存率90.9%(10/11)。

临床怎么用

  • 原文结论认为供者纯化CD34(+)细胞输注可能是治疗再生障碍性贫血患者单倍体造血干细胞移植后造血重建不良的有效方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the safety and efficacy of donor-purified CD34(+) stem cell boosts in patients with poor hematopoietic reconstruction (PHR) after haploid hematopoietic stem cell transplantation (haplo-HSCT) for aplastic anemia (AA) . Method: A retrospective analysis was conducted on 11 patients with AA and PHR who underwent haplo-HSCT and received donor-purified CD34(+) stem cell boosts at Peking University People's Hospital. Recovery of blood cell counts, incidence of graft-versus-host disease (GVHD), and overall survival (OS) were assessed. Results: Of the 11 patients with PHR, two were diagnosed with prolonged isolated thrombocytopenia (PT), one was primary poor graft function (PGF), and eight were diagnosed with secondary PGF. The median time to PHR diagnosis was 110 days (range: 60-330 days), and the median interval from transplantation to purified CD34(+) hematopoietic stem cell infusion was 194 days (range: 125-456 days). The two patients with PT achieved complete platelet recovery at 22 and 13 days after CD34(+) stem cell infusion, respectively. Among the remaining nine patients with PGF, six achieved complete hematopoietic recovery, with a median absolute neutrophil count recovery time of 19 days (8-158 days), HGB recovery time of 32.5 days (range: 13-158 days), and platelet recovery time of 31.5 days (range: 7-171 days). The incidence of chronic GVHD after infusion was 18.2%, with no cases of acute GVHD observed. The OS rate was 90.9% (10/11) in the 11 patients, with a median follow-up of 614 days (range: 153-1 765 days) . Conclusion: Donor-purified CD34(+) stem cell boost may be an effective therapeutic strategy for PHR in patients with AA after haplo-HSCT. 目的: 分析供者纯化CD34(+)细胞输注治疗再生障碍性贫血(AA)患者单倍体造血干细胞移植(haplo-HSCT)后造血重建不良(PHR)的安全性和有效性。 方法: 纳入2019年1月1日至2024年3月31日在北京大学人民医院接受供者CD34(+)细胞输注的11例haplo-HSCT后发生PHR的AA患者,对其输注CD34(+)细胞后造血恢复、移植物抗宿主病(GVHD)发生及预后指标进行回顾性分析。 结果: 11例PHR患者中,持续性血小板减少(PT)2例,原发性植入功能不良(PGF)1例,继发性PGF 8例。诊断PHR的中位时间为移植后110(60~330)d,输注纯化CD34(+)细胞的中位时间为移植后194(125~456)d。以输注CD34(+)细胞后180 d为观察点进行疗效评估,2例PT患者分别在CD34(+)细胞输注后22 d、13 d获得血小板恢复,其余9例PGF患者中6例获得完全造血恢复(CHR),1例评估为部分造血恢复(PR),2例评估为无效(NR)。6例获得CHR患者的中性粒细胞计数中位恢复时间为19(8~158)d,HGB中位恢复时间为32.5(13~158)d,血小板计数中位恢复时间为31.5(7~171)d。供者纯化CD34(+)细胞输注后慢性GVHD发生率为18.2%,未发生急性GVHD。中位随访时间为614(153~1 765)d,11例患者中10例存活。 结论: 供者纯化CD34(+)细胞输注是治疗AA患者haplo-HSCT后PHR的有效方法。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. He Y, Xu ZL, Chen H, et al. [Clinical analysis of donor-purified CD34(+) stem cell boost in 11 patients with poor hematopoietic reconstruction after haploid hematopoietic stem cell transplantation for aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40887417. doi:10.3760/cma.j.cn121090-20240902-00331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。